MHCombiotic
MHCombiotic (MHC) is a preclinical biotech company based in Calgary, Canada, dedicated to combating antimicrobial resistance (AMR) through the development of innovative antimicrobial solutions known as Combiotics™. The company focuses on safe antimicrobial discovery with a low chance of future resistance, utilizing a synergistic combination of plant-based small molecules and inorganic salts. MHC collaborates with top global research institutes and industries to advance its state-of-the-art technology, aiming to provide efficacious and cost-effective solutions to global health challenges.
What We Do
Development of unique antimicrobial formulations for wounds, addressing challenges associated with wound infections, including biofilm prevention and eradication, reduced toxicity, and increased antimicrobial potency.
Investigation of the therapeutic benefits of Combiotic for respiratory infections, offering antibacterial, antibiofilm, antioxidant, and anti-inflammatory effects.
Development of patented non-conventional antibiotic technology targeting mastitis-causing microorganisms, including antibiotic-resistant strains, in dairy cattle.
A flagship product developed after screening over 18,000 novel formulations, designed to control infection and antimicrobial resistance.
Vaccines
Key People
News & Updates
Awarded for pioneering innovative technology in antimicrobial research.
Recognition for significant contributions to antimicrobial research and innovation.
Awarded for pioneering innovative technology in life sciences.